Ghrelin Induces the Production of Hypothalamic NPY Through the AMPK-mTOR Pathway to Alleviate Cancer-induced Bone Pain
In Vivo · 2024
DOI: 10.21873/invivo.13548 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Vivo, 2024. Verfasst von Longjie Xu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Second Affiliated Hospital of Soochow University, Suzhou, P.R. China. Hauptthemen laut MEDLINE: Ghrelin, Hypothalamus, TOR Serine-Threonine Kinases, Neuropeptide Y. Die Arbeit wurde bisher 9-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND/AIM: Cancer-induced bone pain (CIBP) is one of the most common symptoms of bone metastasis of tumor cells. The hypothalamus may play a pivotal role in the regulation of CIBP. However, little is known about the exact mechanisms. MATERIALS AND METHODS: First, we established a CIBP model to explore the relationship among hypothalamic ghrelin, NPY and CIBP. Then, we exogenously administered NPY and NPY receptor antagonists to investigate whether hypothalamic NPY exerted an antinociceptive effect through binding to NPY receptors. Finally, we exogenously administered ghrelin to investigate whether ghrelin alleviated CIBP by inducing the production of hypothalamic NPY through the AMPK-mTOR pathway. Body weight, food intake and behavioral indicators of CIBP were measured every 3 days. Hypothalamic ghrelin, NPY and the AMPK-mTOR pathway were also measured. RESULTS: The expression of hypothalamic ghrelin and NPY was simultaneously decreased in cancer-bearing rats, which was accompanied by CIBP. Intracerebroventricular (i.c.v.) administration of NPY significantly alleviated CIBP in the short term. The antinociceptive effect of NPY was reversed with the i.c.v. administration of the Y1R and Y2R antagonists. The administration of ghrelin activated the AMPK-mTOR pathway and induced hypothalamic NPY production to alleviate CIBP. This effect of ghrelin on NPY and antinociception was reversed with the administration of a GHS-R1α antagonist. CONCLUSION: Ghrelin could induce the production of hypothalamic NPY through the AMPK-mTOR pathway to alleviate CIBP, which can provide a novel therapeutic mechanism for CIBP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Second Affiliated Hospital of Soochow University, Suzhou, P.R. China.
- Department of Thyroid and Breast Surgery, Suzhou Wuzhong People's Hospital, Suzhou, P.R. China.
- Department of General Surgery, Second Affiliated Hospital of Soochow University, Suzhou, P.R. China; caochunnj@163.com.
- Department of General Surgery, Second Affiliated Hospital of Soochow University, Suzhou, P.R. China; lixiaohuasz1981@163.com.
Zitieren
APA
Xu, L., Hou, L., Cao, C., & Li, X. (2024). Ghrelin Induces the Production of Hypothalamic NPY Through the AMPK-mTOR Pathway to Alleviate Cancer-induced Bone Pain. In Vivo. https://doi.org/10.21873/invivo.13548
Vancouver
Xu L, Hou L, Cao C, Li X. Ghrelin Induces the Production of Hypothalamic NPY Through the AMPK-mTOR Pathway to Alleviate Cancer-induced Bone Pain. In Vivo. 2024. doi:10.21873/invivo.13548
BibTeX
@article{Xu2024,
author = {Xu, Longjie and Hou, Lili and Cao, Chun and Li, Xiaohua},
title = {Ghrelin Induces the Production of Hypothalamic NPY Through the AMPK-mTOR Pathway to Alleviate Cancer-induced Bone Pain},
journal = {In Vivo},
year = {2024},
doi = {10.21873/invivo.13548}
}
EUVIMED